January 17, 2024
Last patient enrolled in the ASTORIA Phase 2b clinical trial evaluating JM-010, an innovative therapy to treat Parkinson’s disease dyskinesia
[Hørsholm, January 17th, 2024] – Contera Pharma A/S, a biotech…
Read more
September 27, 2023
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat…
Read more
April 11, 2023
Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform
Abzu® and Contera Pharma expand their strategic partnership to add…
Read more